HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

2'-deoxy-2'-fluoro-2'-C-methylcytidine

PSI-6130 is the (beta-D)-isomer; has antiviral activity against hepatitis C virus; structure in first source
Also Known As:
2'-F-2'-C-MeC; 4-amino-(3-fluoro-4-hydroxy-5-(hydroxymethyl)-3-methyltetrahydrofuran-2-yl)pyrimidin-2(1H)-one; PSI 6130; PSI-6130; PSI6130
Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Ali, Samir: 1 article (12/2008)
2. Alker, Andre: 1 article (12/2008)
3. Cammack, Nick: 1 article (12/2008)
4. Inocencio, Nicole: 1 article (12/2008)
5. Jiang, Wen-Rong: 1 article (12/2008)
6. Kang, Hyunsoon: 1 article (12/2008)
7. Klumpp, Klaus: 1 article (12/2008)
8. Le Pogam, Sophie: 1 article (12/2008)
9. Leveque, Vincent: 1 article (12/2008)
10. Ma, Han: 1 article (12/2008)

Related Diseases

1. Infections
12/01/2008 - "In conclusion, PSI-6130 presents a high barrier to resistance selection in vitro, selects for variants exhibiting only low-level resistance, and lacks cross-resistance with R1479, supporting the continued development of the prodrug R7128 as a therapeutic agent for the treatment of HCV infection."
09/01/2008 - "Foremost among the newly described antiviral agents that may be developed into drugs are, for the treatment of human papilloma virus (HPV) infections, cPrPMEDAP; for the treatment of herpes simplex virus (HSV) infections, BAY 57-1293; for the treatment of varicella-zoster virus (VZV) infections, FV-100 (prodrug of Cf 1743); for the treatment of cytomegalovirus (CMV) infections, maribavir; for the treatment of poxvirus infections, ST-246; for the treatment of hepatitis B virus (HBV) infections, tenofovir disoproxil fumarate (TDF) (which in the meantime has already been approved in the EU); for the treatment of various DNA virus infections, the hexadecyloxypropyl (HDP) and octadecyloxyethyl (ODE) prodrugs of cidofovir; for the treatment of orthomyxovirus infections (i.e., influenza), peramivir; for the treatment of hepacivirus infections (i.e., hepatitis C), the protease inhibitors telaprevir and boceprevir, the nucleoside RNA replicase inhibitors (NRRIs) PSI-6130 and R1479, and various non-nucleoside RNA replicase inhibitors (NNRRIs); for the treatment of human immunodeficiency virus (HIV) infections, integrase inhibitors (INIs) such as elvitegravir, nucleoside reverse transcriptase inhibitors (NRTIs) such as apricitabine, non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as rilpivirine and dapivirine; and for the treatment of both HCV and HIV infections, cyclosporin A derivatives such as the non-immunosuppressive Debio-025."
2. Papillomavirus Infections
3. HIV Infections (HIV Infection)
4. Poxviridae Infections
5. Orthomyxoviridae Infections

Related Drugs and Biologics

1. Prodrugs
2. 4'-azidocytidine
3. Integrase Inhibitors
4. Reverse Transcriptase Inhibitors
5. Cyclosporine (Ciclosporin)
6. RNA-Dependent RNA Polymerase (RNA Dependent RNA Polymerase)
7. Protease Inhibitors (Protease Inhibitor)
8. Nucleosides
9. Antiviral Agents (Antivirals)
10. Cidofovir (Vistide)